A small biotech launched a legal battle Wednesday with the Food and Drug Administration, claiming the regulator's recent ...
AbbVie may not be harming its Humira sales when it launches a second rheumatoid arthritis drug, upadacitinib, later this year ...
With no manufacturing capacity of its own, Axovant is dependent on partnerships as it works to bring its first therapies to market. The company currently has agreements with Oxford BioMedica and ...
The Food and Drug Administration on Tuesday convened a public meeting to discuss the value and risks of strong doses of opioids. Over the course of two days, members from two FDA advisory committees ...
Eli Lilly's injectable diabetes drug Trulicity reduced the risk of heart attacks, stroke and cardiovascular death by 12% when ...
Sanofi announced a "voluntary departure program" to reduce its R&D departments in France and Germany by 466 workers, as it shifts away from cardiovascular drug development and toward activities in ...
Regeneron and Sanofi said Friday their experimental IL-33 antibody improved asthma control better than placebo in a Phase 2 study. But REGN3500 didn't beat the two drugmakers' other drug Dupixent, ...
NEW YORK — Merck & Co.'s investor day suggested it is a company on top. Stage lights turned the tall, white walls of 583 Park Avenue a blueish green, reminiscent of the drugmaker's logo. Rows of ...
A combination of Cotellic and Tecentriq failed to beat Keytruda monotherapy in newly diagnosed patients with non-mutated melanoma in a Phase 3 trial, according to an announcement from Cotellic's ...
Contracted services provider Catalent is growing its European business, announcing plans on Wednesday to buy an Italy-based manufacturing facility from Bristol-Myers Squibb. The facility makes oral ...
Sanofi's foothold in the hemophilia drug market is barely a year old but already looks shaky. For two decades, drugs treating the rare blood disorder required multiple infusions each week. Among them ...
As Teva's financial problems have continued to mount, one Wall Street bank slashed its stock price target Wednesday by more than one-third, flagging concerns with the Israeli giant's financial health. ...